Covid 19 and Endocrinology

Diabetes plays a significant role in this phenotype because it is one of the most common comorbidities linked to COVID-19 severity and mortality. Careful management, including treatment changes, may be required to protect our patients from the most serious effects of COVID-19, whether they have diabetes or are hospitalised with COVID-19, as well as patients with SARS-CoV-2-induced recently onset diabetes. Obesity raises vulnerability to SARS-CoV-2 and the chance of a negative COVID-19 result.

    Related Conference of Covid 19 and Endocrinology

    September 09-10, 2024

    33rd International Diabetes and Healthcare Conference

    Paris, France
    September 09-10, 2024

    7th Annual Meeting on Diabetes and Endocrinology

    Paris, France
    September 09-10, 2024

    4th European Endocrinology and Diabetes Congress

    Paris, France
    September 25-26, 2024

    5th World Summit on Diabetes Expo

    Rome, Italy
    October 14-15, 2024

    3rd International Summit on Hormonal Disorders

    Madrid, Spain
    November 22-23, 2024

    20th World Congress on Endocrinology & Diabetes

    Amsterdam, Netherlands

    Covid 19 and Endocrinology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in